Kopp, Hans-Georg
Robert Bosch Hospital
4 papers on CoChatORCID 0000-0002-0825-8888
Most cited papers
- Verified
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 1,662
- Verified
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism
Chemotherapy-related skin toxicityLung Cancer Treatments and Mutations
Cited by 630
- Verified
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., et al. (2021) · Nature Communications
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 175
- Verified
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
Cappuzzo, F., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2018) · Annals of Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 57
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free